Cbot — Merger or Acquisition (June 2007)
30 slides from Cbot's merger presentation, Jun 26, 2007
Slide 1: Filed by CBOT Holdings, Inc. Pursuant to Rule 425
Filed by CBOT Holdings, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company CBOT Holdings, Inc. (Commission File No. 001-32650)
Slide 2: CBOT/CME: A Combination to Compete Successfully in the Global Marketplace
CBOT/CME: A Combination to Compete Successfully in the Global Marketplace June 25, 2007 Presentation to Members
Slide 3: Forward Looking Statements
Forward Looking Statements JUNE 2007 Certain statements in this presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and includes any use of the words “may,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “e
Slide 4: Discussion Overview
Discussion Overview CME/CBOT Strategic Rationale CME/CBOT Merger Enhancements Transaction Summary One-Time Dividend Exercise Rights and Member Rights Stock Valuation Risks Associated with ICE Proposal Summary
Slide 5: Transaction Summary
Transaction Summary For each CBOT share, shareholders will receive 0.3500 CME shares Consideration: All stock transaction; cash election eliminated CME Shareholders: 65.4% Pro Forma Ownership: CBOT Shareholders: 34.6% Accretive to earnings of the combined company on a cash basis within 12 months and
Slide 6: One-Time Dividend Payment
One-Time Dividend Payment All CBOT stockholders would receive a cash dividend of $9.14 per share of Class A common stock if the CBOT/CME merger closes The CBOT Holdings Board will set and announce a record date prior to the July 9th vote If you own the stock as of the record date, you would be entit
Slide 7: ERP Guarantee
ERP Guarantee The $15 million cap on the Delaware litigation has been eliminated Exercise Right holders will have the option to: OPTION 1: cash out shortly after the merger closes by selling your exercise right to the CBOT OR OPTION 2: stay in the litigation, in which case the CBOT will guarantee a
Slide 8: ERP Guarantee – Option 1 – Cash Out
ERP Guarantee – Option 1 – Cash Out If you held a Series B-1 membership and an exercise right as of May 29, 2007, the record date for the merger vote, and you want to cash out: The CBOT will buy your exercise right for approximately $250,000 So B-1 members with 27,338 shares could get a total of $50
Slide 9: ERP Guarantee – Option 2 – Stay in the Litigation
ERP Guarantee – Option 2 – Stay in the Litigation If you want to remain in the litigation: The CBOT will guarantee that class members receive no less than $250,000 in value for their exercise right If class members receive less than $250,000 in value, the CBOT would pay the difference in cash to eac
Slide 10: Exercise Rights
Exercise Rights Exercise right holders represented as a class by separate counsel in Delaware litigation The ICE/CBOE proposal would require the approval of the court and the class plaintiff in the Delaware litigation In Delaware litigation we are seeking equal treatment of CBOT Eligible Full Member
Slide 11: Exercise Rights
Exercise Rights Our position that the conditions of the 1992 Agreement are satisfied in connection with the CME merger is well founded The surviving entity is an exchange (CBOT will continue to exist as an exchange after the merger) CBOT full members will be granted membership in the surviving entit
Slide 12: Member Rights Better Protected Under CME Agreement
Member Rights Better Protected Under CME Agreement CBOT designates individuals to serve as CBOT directors on combined company’s board extended until 2012 Until 2012, rule changes that would impair business opportunities (i.e. member fee preferences) of CBOT members would need approval by committee t
Slide 13: Core Rights Provisions
Core Rights Provisions The following provisions cannot be changed without the vote of the B-1 and B-2 members: Number of authorized B-1 and B-2 memberships Allocation of products among members Right of B-1 members to trade all new products on CME or CBOT Right to lower fees than non-members Membersh
Slide 14: Core Rights Provisions - continued
Core Rights Provisions - continued No minimum fee preference, but: Until 2012, CME can’t change fees without CBOT Director-controlled rules committee approval After 2012, you will still have the same core right you have today - member fees must be lower than non-member fees More importantly, CME’s p
Slide 15: Tender Offer Availability
Tender Offer Availability Reconfirming CME’s Commitment The CME will make a $3.5 billion cash tender offer at $560 a share shortly following the closing If the CME stock you receive in the merger is trading below $560 per share, you can sell a portion of it back to the CME for $560 per share If the
Slide 16: CME/CBOT: A Strategic Fit
CME/CBOT: A Strategic Fit Creates world’s largest futures exchange Clearly aligned with CBOT’s strategic vision Better positioned to pursue immediate and long term growth opportunities Entails low integration and execution risk Better able to compete and win in changing global marketplace
Slide 17: CME and CBOT Merger Offers Substantial Advantages to Stockholders and Members
CME and CBOT Merger Offers Substantial Advantages to Stockholders and Members Immediate Cash Payments; Not Contingent on Stock Price or cap Better protection of members’ rights Exercise right guarantee provides certainty and choice to holders, and retains ability to participate in any upside from li
Slide 18: CME Combination Clearly Aligned with CBOT Strategic Vision
CME Combination Clearly Aligned with CBOT Strategic Vision Expands access to global markets Offers innovative new trading opportunities Enhances depth and breadth of liquidity that we provide the market place Provides long-term value to stockholders and members
Slide 19: Better Positioned for Immediate and Long-Term Growth Opportunities
Better Positioned for Immediate and Long-Term Growth Opportunities Can immediately pursue OTC growth opportunities Greater diversity of revenues Complementary products create opportunities for significant revenue/growth synergies Financials, equities and agricultural products Both organizations have
Slide 20: Entails Low Integration and Execution Risk
Entails Low Integration and Execution Risk Builds on strong productive relationship between CME and CBOT over many years CME and CBOT have proven track record in integration Successful integration of CCL in 9 months CME integration of NYMEX in 2 months Speed to integration Migration to Globex expect
Slide 21: Substantial Synergy Potential: Realizable & Certain
Substantial Synergy Potential: Realizable & Certain Cost synergies of $150 million already identified Includes technology, trading floor consolidation and administrative Expected to be accretive to earnings on a cash basis within 12 months and on GAAP basis within 12-18 months Share repurchase expec
Slide 22: Opportunities for Significant Revenue Synergies
Opportunities for Significant Revenue Synergies Large Scalable Platforms • Trade matching • Clearing processing Product Innovation Broadest Global Presence • Yield curve products • Immediate customer base • Spread products/functionalities $75 growth in 80+ countries • Strong entry point for credit,
Slide 23: Improved Competitiveness in Global Marketplace
Improved Competitiveness in Global Marketplace Combined organization will be better positioned to compete globally Environment is changing rapidly with increased consolidation and this combination allows us to succeed on global basis Can pursue untapped global growth Customers in more than 80 countr
Slide 24: Agreement with CME Allows Us to Successfully Compete Globally
Agreement with CME Allows Us to Successfully Compete Globally The CME/CBOT merger creates the world’s largest futures exchange and significant long-term value for CBOT Holdings’ stockholders, members and customers A merged CME/CBOT will be better able to compete globally in a rapidly changing indust
Slide 25: ICE Proposal Contains Greater Contingencies
ICE Proposal Contains Greater Contingencies Cash Election Value contingent upon ICE stock price at time of close of merger; CME tender offer provides a fixed price of $560 per share post close Dividend Payment Lower dividend payout - dividend payment of $0.29 per share for the third and fourth quart
Slide 26: Combination with ICE Presents Significant Risks
Combination with ICE Presents Significant Risks Risks related to integration and execution and, thus, to the long-term value of combined company Functionality and scale of ICE’s clearing and electronic platform would need to be significantly increased to support CBOT customers and trading volume Mig
Slide 27: Combination with ICE Presents Significant Risks
Combination with ICE Presents Significant Risks Integration would be overseen and managed by a board comprised of a majority of ICE directors and ICE management Product development may be adversely affected during migration to ICE platform Loss of critical personnel during migration creates addition
Slide 28: ICE Leverage Comparison
ICE Leverage Comparison ICE would be more leveraged to fund transaction Need to service debt could restrict strategic growth alternatives Although the CME transaction as proposed initially takes on more debt, the stronger combined balance sheet and future cash flows result in a more manageable level
Slide 29: Additional Risk Associated with ICE Currency
Additional Risk Associated with ICE Currency Current stock price vs intrinsic value 06/22/2007 stock price Range of intrinsic value $300 $700 $220 280 650 200 $632 260 240 600 180 220 $554 $204 550 160 200 $149 180 500 140 $169 $496 160 $160 450 120 140 $436 $114 $133 120 400 100 Base case Base plus
Slide 30: CME/CBOT: A Strategic Fit
CME/CBOT: A Strategic Fit Creates world’s largest futures exchange Clearly aligned with CBOT’s strategic vision Better positioned to pursue immediate and long-term growth opportunities Entails low integration and execution risk Better able to compete and win in changing global marketplace